文献速递胸部肿瘤

Olomorasib联合帕博利珠单抗治疗KRAS G12C突变晚期NSCLC的疗效与安全性

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.
PubMed 文献 · J Thorac Oncol · 2025-11-29

LOXO-RAS-20001是一项1/2期试验,评估Olomorasib联合帕博利珠单抗治疗KRAS G12C突变晚期NSCLC。在91例可评估患者中,总体客观缓解率为57.1%,一线为73.9%,一线且PD-L1≥50%为90%,安全性可控。

要点

  • 联合方案在KRAS G12C突变晚期NSCLC中显示 promising 抗肿瘤活性。
  • 一线PD-L1≥50%患者ORR达90%,提示该人群获益显著。
  • ≥3级治疗相关不良事件发生率为33.3%,需关注毒性管理。

核心结论

  • Olomorasib联合帕博利珠单抗在KRAS G12C突变晚期NSCLC中安全性可控,并在各PD-L1表达水平显示抗肿瘤活性,尤其一线高PD-L1表达者。

研究设计与样本

  • 1/2期试验LOXO-RAS-20001纳入99例晚期KRAS G12C突变NSCLC患者,评估Olomorasib(50、100、150 mg每日两次)联合帕博利珠单抗。

主要发现

  • 93例接受50或100 mg每日两次治疗的患者中,81.7%发生任何级别治疗相关不良事件,最常见为腹泻(34.4%)和ALT/AST升高(24.7%/22.6%)。
  • ≥3级治疗相关不良事件发生率为33.3%,20.4%患者因不良事件减量Olomorasib,6.5%患者因不良事件停用两种治疗。
  • 91例可评估患者中,中位随访12.5个月,总体客观缓解率为57.1%(95%CI 46.3-67.5)。
  • 一线治疗患者客观缓解率为73.9%(95%CI 58.9-85.7),一线且PD-L1≥50%患者为90%(95%CI 68.3-98.8)。

临床怎么用

  • 对于KRAS G12C突变晚期NSCLC,尤其一线PD-L1≥50%患者,可考虑Olomorasib联合帕博利珠单抗治疗。
  • 治疗期间需密切监测腹泻和肝酶升高,及时处理不良事件并调整剂量。

局限性

  • 样本量有限,随访时间较短,需更大规模研究验证。
  • 未报告随机对照数据,无法直接比较联合方案与标准治疗的优劣。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immunotherapy-based regimens are the standard first-line treatment for KRAS G12C-mutant NSCLC, but outcomes remain suboptimal. Prior attempts to combine KRAS G12C inhibitors with immunotherapy have been challenged by toxicity. We report results from LOXO-RAS-20001, a phase 1/2 trial evaluating the combination of olomorasib with pembrolizumab in KRAS G12C-mutant NSCLC, including in first-line setting. METHODS: Patients with advanced KRAS G12C-mutant NSCLC in any treatment line, including prior KRAS G12Ci and immunotherapy were eligible. Any PD-L1 level (0%-100%) was permitted. Three dose levels of olomorasib (50, 100, and 150 mg twice daily) plus pembrolizumab were evaluated, focusing on 50 and 100 mg twice daily for safety and efficacy. RESULTS: A total of 99 enrolled patients had a median age of 68 (range, 42-83) years; 52% of tumors were PD-L1 0% to 49%, 36% were PD-L1 more than or equal to 50%, and 51% were first line. Of 93 patients treated at 50 or 100 mg twice daily, 76 (81.7%) experienced treatment-related adverse event (TRAEs) of any grade, most often, diarrhea (34.4%) and increased alanine aminotransferase/aspartate aminotransferase level (24.7%/22.6%). Grade more than or equal to 3 TRAEs were found in 33.3%. TRAEs led to olomorasib dose reductions in 20.4% and discontinuation of both therapies in 6.5% of patients. Among 91 efficacy-evaluable patients, at a median follow-up of 12.5 months (interquartile range, 6.2-16.9), objective response rate was 57.1% (95% confidence interval [CI], 46.3-67.5) across all PD-L1 expression levels, 73.9% (95% CI, 58.9-85.7) in first line, and 90% (95% CI, 68.3-98.8) in first-line patients with PD-L1 more than or equal to 50%. CONCLUSION: Olomorasib plus pembrolizumab demonstrated manageable safety and promising antitumor activity in patients with KRAS G12C-mutant advanced NSCLC across PD-L1 expression levels, especially in the high PD-L1 first-line setting.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Burns TF, Ammakkanavar NR, Hollebecque A, et al. Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC. J Thorac Oncol. 2025. PMID: 41319864. doi:10.1016/j.jtho.2025.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。